|
시장보고서
상품코드
2055160
생물제제 수탁 제조 시장 : 서비스 유형별, 생물제제 유형별, 생산 시스템별, 규모별, 기업 규모별, 치료 영역별, 지역별Biologics Contract Manufacturing Market, By Service Type, By Biologic Type, By Production System, By Scale, By Company Size, By Therapeutic Area, By Geography |
||||||
생물제제 수탁 제조 시장은 2026년에 397억 2,000만 달러에 달하고 2033년까지 804억 달러에 이를 것으로 예상되고 있습니다. 2026-2033년 CAGR은 10.6%를 나타낼 전망입니다.
| 분석 범위 | 분석 상세 | ||
|---|---|---|---|
| 기준 연도 | 2025년 | 시장 규모(2026년) | 397억 2,000만 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2026-2033년 |
| 예측 기간 CAGR(2026-2033년) | 10.60% | 예측 금액(2033년) | 804억 달러 |
세계 생물제제 수탁 제조 시장은 제약 아웃소싱 업계의 중요한 부문으로, 단일클론 항체, 백신, 세포 및 유전자 치료제, 재조합 단백질 등 복잡한 바이오의약품에 대한 전문적인 제조 서비스를 포괄하고 있습니다. 이 시장은 외부 전문 지식, 첨단 제조 역량, 규제 준수를 활용하면서 운영 비용을 최적화하고, 생명을 구하는 치료법 시장 출시 기간을 단축하고자 하는 제약사 및 바이오기술 기업들에게 전략적 솔루션으로 부상하고 있습니다.
이 분야의 수탁 제조 기업(CMO)은 공정 개발 및 스케일업부터 상업 생산, 품질 관리, 규제 대응에 이르기까지 종합적인 서비스를 제공합니다. 생물제제의 복잡성이 증가함에 따라, 엄격한 규제 요건과 최첨단 제조 시설에 필요한 막대한 설비 투자가 맞물리면서, 전통 있는 대형 제약사부터 신생 바이오기술 기업에 이르기까지 아웃소싱 전략의 도입이 가속화되고 있습니다. 이 시장은 종양학, 자가면역질환, 감염증, 희귀질환 등 다양한 치료 분야를 아우르며, 제조 서비스는 초기 단계의 임상시험용 시료부터 대규모 상업 생산에 이르기까지 폭넓게 제공됩니다. 따라서, 이는 현대 바이오의약품 밸류체인에서 필수적인 요소로 자리 잡고 있습니다.
시장 역학
세계 생물제제 수탁 제조 시장은 몇 가지 강력한 촉진요인에 의해 주도되고 있습니다. 그 주된 요인은 바이오의약품 파이프라인 개발이 기하급수적으로 확대되고 있다는 점으로, 현재 전 세계적으로 7,000건 이상의 바이오의약품이 임상 개발의 다양한 단계에 있으며, 이는 전문적인 제조 능력에 대한 전례 없는 수요를 창출하고 있습니다. 바이오의약품의 복잡화, 특히 CAR-T 세포 치료나 유전자 치료와 같은 첨단 치료법의 경우, 고도의 제조 노하우가 필요하지만, 많은 기업은 이를 자체적으로 개발하기보다는 외부에 위탁하는 것을 선호합니다. 승인된 의약품 1개당 26억 달러를 초과하기도 하는 개발 비용의 상승에 더해, 전문적인 시설과 장비, 그리고 규제 관련 전문 지식이 필요하기 때문에 위탁 생산은 매력적인 비용 최적화 전략으로 자리 잡고 있습니다.
게다가 만성 질환 유병률 증가와 전 세계적인 고령화 추세가 지속되는 가운데, 생물제제를 이용한 치료에 대한 수요는 계속해서 증가하고 있습니다. 그러나 시장에는 중대한 제약도 존재합니다. 여기에는 규정 준수상의 문제나 지연을 초래할 수 있는 엄격한 규제 요건, 제품의 균일성이나 안전성에 영향을 미칠 수 있는 품질 관리의 복잡성, 그리고 코로나19 팬데믹 기간 동안 드러난 공급망의 취약성 등이 포함됩니다. 지적 재산권과 관련된 우려나 기술 이전의 문제점 또한 아웃소싱 결정에 있어 걸림돌이 되고 있습니다. 이러한 과제가 있음에도 불구하고, 비용 효율이 높은 제조 솔루션이 요구되는 바이오시밀러 시장의 확대, 맞춤형 의료 및 세포 치료에 대한 수요 증가, 신흥 시장에서의 바이오의약품 활동 확대, 그리고 바이오의약품 생산의 효율성과 유연성을 높이는 연속 제조 기술 및 일회용 기술의 발전 등 큰 기회가 생겨나고 있습니다.
본 보고서의 주요 특징
- 본 보고서는 각 부문의 잠재적 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한 시장 성장 촉진요인과 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채택하는 경쟁 전략 등에 관한 중요한 분석도 제공합니다.
- 전 세계 생물제제 수탁 제조 시장의 주요 기업 프로파일을 다양한 지표(기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략 등)를 바탕으로 소개합니다.
- 본 보고서의 인사이트를 바탕으로, 마케팅 담당자와 기업 경영진은 향후 제품 출시, 제품 라인업 개편, 시장 확대 및 마케팅 전략에 관해 충분한 정보를 바탕으로 의사결정을 내릴 수 있습니다.
- ‘세계 생물제제 수탁 제조 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계의 생물제제 수탁 제조 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 보다 수월하게 할 수 있습니다.
목차
제1장 분석 목적 및 전제 조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 생물제제 수탁 제조 시장 : 서비스 유형별(2021-2033년)
제5장 세계의 생물제제 수탁 제조 시장 : 생물제제 유형별(2021-2033년)
제6장 세계의 생물제제 수탁 제조 시장 : 생산 시스템별(2021-2033년)
제7장 세계의 생물제제 수탁 제조 시장 : 규모별(2021-2033년)
제8장 세계의 생물제제 수탁 제조 시장 : 기업 규모별(2021-2033년)
제9장 세계의 생물제제 수탁 제조 시장 : 치료 영역별(2021-2033년)
제10장 세계의 생물제제 수탁 제조 시장 : 지역별(2021-2033년)
제11장 경쟁 구도
제12장 애널리스트의 제안
제13장 참고 문헌 및 분석 방법
KTH 26.06.19Biologics Contract Manufacturing Market is estimated to be valued at USD 39.72 Bn in 2026 and is expected to reach USD 80.40 Bn by 2033, growing at a compound annual growth rate (CAGR) of 10.6% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 39.72 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 10.60% | 2033 Value Projection: | USD 80.40 Bn |
The global biologics contract manufacturing market represents a critical segment of the pharmaceutical outsourcing industry, encompassing specialized manufacturing services for complex biological products including monoclonal antibodies, vaccines, cell and gene therapies, and recombinant proteins. This market has emerged as a strategic solution for pharmaceutical and biotechnology companies seeking to leverage external expertise, advanced manufacturing capabilities, and regulatory compliance while optimizing operational costs and accelerating time-to-market for life-saving therapies.
Contract manufacturing organizations (CMOs) in this space provide comprehensive services ranging from process development and scale-up to commercial manufacturing, quality control, and regulatory support. The increasing complexity of biological products, coupled with stringent regulatory requirements and substantial capital investments required for state-of-the-art manufacturing facilities, has driven the adoption of outsourcing strategies among both established pharmaceutical giants and emerging biotech companies. The market encompasses various therapeutic areas including oncology, autoimmune diseases, infectious diseases, and rare disorders, with manufacturing services spanning from early-phase clinical trial materials to large-scale commercial production, making it an indispensable component of the modern biopharmaceutical value chain.
Market Dynamics
The global biologics contract manufacturing market is propelled by several compelling drivers, primarily the exponential growth in biologics pipeline development, with over 7,000 biologics currently in various stages of clinical development worldwide, creating unprecedented demand for specialized manufacturing capacity. The increasing complexity of biological products, particularly advanced therapies like CAR-T cell therapies and gene therapies, requires sophisticated manufacturing expertise that many companies prefer to outsource rather than develop in-house. Rising development costs, which can exceed USD 2.6 billion per approved drug, coupled with the need for specialized facilities, equipment, and regulatory expertise, make contract manufacturing an attractive cost-optimization strategy.
Additionally, the growing prevalence of chronic diseases and aging global population continues to drive demand for biologic treatments. However, the market faces significant restraints including stringent regulatory requirements that can create compliance challenges and delays, quality control complexities that can impact product consistency and safety, and supply chain vulnerabilities exposed during the COVID-19 pandemic. Intellectual property concerns and technology transfer challenges also pose barriers to outsourcing decisions. Despite these challenges, substantial opportunities emerge from the expanding biosimilars market, which requires cost-effective manufacturing solutions, increasing demand for personalized medicine and cell-based therapies, growing biopharmaceutical activities in emerging markets, and technological advancements in continuous manufacturing and single-use technologies that enhance efficiency and flexibility in biologics production.
Key Features of the Study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global biologics contract manufacturing market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Lonza, Thermo Fisher Scientific, Catalent, Samsung Biologics, WuXi Biologics, Boehringer Ingelheim BioXcellence, Fujifilm Diosynth Biotechnologies, AGC Biologics, Recipharm, Siegfried, Rentschler Biopharma, Abzena, Charles River Laboratories, IDT Biologika, and Avid Bioservices
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global biologics contract manufacturing market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global biologics contract manufacturing market
Market Segmentation
- Service Type Insights (Revenue, USD Bn, 2021 - 2033)
- Drug substance/Active Pharmaceutical Ingredient (API) Manufacturing
- Drug product/Formulation and Fill-Finish (FDF)
- Analytical and Quality Control services
- Process development and scale-up/Technology transfer
- Packaging, labeling and ancillary services
- Biologic Type Insights (Revenue, USD Bn, 2021 - 2033)
- Monoclonal antibodies (mAbs)
- Recombinant proteins and enzymes
- Vaccines
- Cell and gene therapies
- Antibody-drug conjugates (ADCs)
- Others (growth factors, cytokines, fusion proteins)
- Production System Insights (Revenue, USD Bn, 2021 - 2033)
- Mammalian systems (CHO, NS0, HEK)
- Microbial systems (E. coli, yeast)
- Alternative/Emerging systems (insect cells, plant, cell-free)
- Scale Insights (Revenue, USD Bn, 2021 - 2033)
- Preclinical/clinical scale manufacturing
- Commercial scale manufacturing
- Company Size Insights (Revenue, USD Bn, 2021 - 2033)
- Small to Mid-sized Contract Manufacturers
- Large Contract Manufacturing Organizations (CMOs/CDMOs)
- Therapeutic Area Insights (Revenue, USD Bn, 2021 - 2033)
- Oncology/Hematology
- Immunology and Autoimmune Disorders
- Infectious Diseases and Vaccinology
- Cardiovascular and Renal Disorders
- Neurology and Central Nervous System (CNS) Disorders
- Metabolic and Endocrine Disorders (e.g., diabetes, obesity, thyroid)
- Respiratory Disorders
- Others (Dermatology, Rare and Orphan Diseases)
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Lonza
- Thermo Fisher Scientific
- Catalent
- Samsung Biologics
- WuXi Biologics
- Boehringer Ingelheim BioXcellence
- Fujifilm Diosynth Biotechnologies
- AGC Biologics
- Recipharm
- Siegfried
- Rentschler Biopharma
- Abzena
- Charles River Laboratories
- IDT Biologika
- Avid Bioservices
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Biologics Contract Manufacturing Market, By Service Type
- Global Biologics Contract Manufacturing Market, By Biologic Type
- Global Biologics Contract Manufacturing Market, By Production System
- Global Biologics Contract Manufacturing Market, By Scale
- Global Biologics Contract Manufacturing Market, By Company Size
- Global Biologics Contract Manufacturing Market, By Therapeutic Area
- Global Biologics Contract Manufacturing Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Biologics Contract Manufacturing Market, By Service Type, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Drug substance/Active Pharmaceutical Ingredient (API) Manufacturing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Drug product/Formulation and Fill-Finish (FDF)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Analytical and Quality Control services
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Process development and scale-up/Technology transfer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Packaging, labeling and ancillary services
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
5. Global Biologics Contract Manufacturing Market, By Biologic Type, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Monoclonal antibodies (mAbs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Recombinant proteins and enzymes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Cell and gene therapies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Antibody-drug conjugates (ADCs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Others (growth factors, cytokines, fusion proteins)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
6. Global Biologics Contract Manufacturing Market, By Production System, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Mammalian systems (CHO, NS0, HEK)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Microbial systems (E. coli, yeast)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Alternative/Emerging systems (insect cells, plant, cell-free)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
7. Global Biologics Contract Manufacturing Market, By Scale, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Preclinical/clinical scale manufacturing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Commercial scale manufacturing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
8. Global Biologics Contract Manufacturing Market, By Company Size, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Small to Mid-sized Contract Manufacturers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Large Contract Manufacturing Organizations (CMOs/CDMOs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
9. Global Biologics Contract Manufacturing Market, By Therapeutic Area, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Oncology/Hematology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Immunology and Autoimmune Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Infectious Diseases and Vaccinology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Cardiovascular and Renal Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Neurology and Central Nervous System (CNS) Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Metabolic and Endocrine Disorders (e.g., diabetes, obesity, thyroid)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Respiratory Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Others (Dermatology, Rare and Orphan Diseases)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
10. Global Biologics Contract Manufacturing Market, By Region, 2021 - 2033, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Service Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Biologic Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Production System, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Scale, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Company Size, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Service Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Biologic Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Production System, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Scale, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Company Size, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Service Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Biologic Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Production System, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Scale, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Company Size, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Service Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Biologic Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Production System, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Scale, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Company Size, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Service Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Biologic Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Production System, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Scale, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Company Size, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Service Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Biologic Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Production System, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Scale, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Company Size, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
11. Competitive Landscape
- Lonza
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Thermo Fisher Scientific
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Catalent
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Samsung Biologics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- WuXi Biologics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Boehringer Ingelheim BioXcellence
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Fujifilm Diosynth Biotechnologies
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AGC Biologics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Recipharm
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Siegfried
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Rentschler Biopharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Abzena
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Charles River Laboratories
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- IDT Biologika
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Avid Bioservices
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
12. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
13. References and Research Methodology
- References
- Research Methodology
- About Us
